Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (161-170 of 446) with videos related to

Pageof 45
Sort By:
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Bone Marrow Transplantation|August 6, 2013
Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCTS V Glavey, M A Gertz, A Dispenzieri, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Blood|December 8, 2011
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementSumit Madan, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|December 17, 2016
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent eraR Chakraborty, E Muchtar, S K Kumar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2017
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk CytogeneticsRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Haematologica|May 6, 2017
Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 29, 2015
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiencyStefan Cordes, Morie A Gertz, Francis K Buadi, et al.
Pageof 45

Showing results (161-170 of 446) with videos related to

Sort By:
Pageof 45
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Bone Marrow Transplantation|August 6, 2013
Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCTS V Glavey, M A Gertz, A Dispenzieri, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Blood|December 8, 2011
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementSumit Madan, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|December 17, 2016
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent eraR Chakraborty, E Muchtar, S K Kumar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2017
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk CytogeneticsRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Haematologica|May 6, 2017
Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 29, 2015
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiencyStefan Cordes, Morie A Gertz, Francis K Buadi, et al.
Pageof 45